AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25710539 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week multimodal physiotherapy programme (MPP) including land-based therapeutic exercise and adapted swimming
Number of subjects: 175
Study 25710539 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week multimodal physiotherapy programme (MPP)
Number of subjects: 175
Study 25710659 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversal of anticoagulation with INR <1.3 within 4 hours after admission
Number of subjects: 1176
Study 25710659 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP <160 mm Hg at 4 hours
Number of subjects: 1176
Study 25710659 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of INR reversal <1.3 within 4 hours and systolic BP <160 mm Hg at 4 hours
Number of subjects: 1176
Study 25710659 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC resumption
Number of subjects: 1176
Study 25710659 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC resumption in patients with atrial fibrillation
Number of subjects: 1176
Study 25710659 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional long-term outcome
Number of subjects: 1176
Study 25710773 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbent Hemodialysis (Allient system; Renal Solutions, Warrendale, PA)
Number of subjects: 18
Study 25710773 — intervention group
Group type: COMPARATOR
Intervention: Single-pass Hemodialysis
Number of subjects: 18
Study 25710812 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric contractility modulation (GCM) device, laparoscopic implantation, n=8
Number of subjects: 16
Study 25710812 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy, n=8
Number of subjects: 16
Study 25710823 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 160
Study 25710823 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants
Number of subjects: 160
Study 25710823 — intervention group
Group type: COMPARATOR
Intervention: WHO Growth Standards
Number of subjects: 160
Study 25710916 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of the autonomous nervous system (ANS) measured through heart rate variability and skin conductance
Number of subjects: 0
Study 25710916 — intervention group
Group type: COMPARATOR
Intervention: Real life situation (2 hours) and quiet environment (30 minutes) with stressful sound
Number of subjects: 0
Study 25710916 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview to record feelings about events triggering anxiety
Number of subjects: 0
Study 25711274 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography
Number of subjects: 475
Study 25711274 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion imaging
Number of subjects: 475
Study 25711274 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall motion imaging
Number of subjects: 475
Study 25711328 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests administered (QNPZ-8 score)
Number of subjects: 608
Study 25711328 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical location
Number of subjects: 608
Study 25711328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild neurocognitive impairment (NCI) defined as z-scores < -1 in at least two of six cognitive domains
Number of subjects: 608
Study 25711317 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25711640 — intervention group
Group type: EXPERIMENTAL
Intervention: African descent (AD) subjects
Number of subjects: 84
Study 25711640 — intervention group
Group type: COMPARATOR
Intervention: European descent (ED) subjects
Number of subjects: 84
Study 25711640 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AD and ED participants
Number of subjects: 84
Study 25712199 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosegment ALPPS hepatectomy
Number of subjects: 12
Study 25712310 — intervention group
Group type: EXPERIMENTAL
Intervention: TOOKAD(®) Soluble at 4 mg/kg
Number of subjects: 117
Study 25712364 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir monotherapy for 14 days followed by telaprevir-based triple therapy after 4.3 to 5.7 years
Number of subjects: 9
Study 25712364 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir-based triple therapy
Number of subjects: 9
Study 25712496 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (expiratory pressures ranged from 10 to 40 mm Hg)
Number of subjects: 9
Study 25712496 — intervention group
Group type: COMPARATOR
Intervention: Breath holds ending on either inhalation or exhalation
Number of subjects: 9
Study 25712687 — intervention group
Group type: EXPERIMENTAL
Intervention: BI-505 (0.09 mg/kg or higher doses)
Number of subjects: 35
Study 25712687 — intervention group
Group type: EXPERIMENTAL
Intervention: BI-505 (escalating doses from 0.0004 to 20 mg/kg)
Number of subjects: 35
Study 25712687 — intervention group
Group type: EXPERIMENTAL
Intervention: BI-505 (10 mg/kg doses)
Number of subjects: 35
Study 25712687 — intervention group
Group type: EXPERIMENTAL
Intervention: BI-505 (various doses)
Number of subjects: 35
Study 25713216 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D (123)I-mIBG innervation maps
Number of subjects: 15
Study 25713286 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25713293 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB therapy
Number of subjects: 0
Study 25713436 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 (trastuzumab emtansine)
Number of subjects: 153
Study 25713436 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 plus radiotherapy
Number of subjects: 153
Study 25713585 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel (Crinone 8% gel) + intercourse
Number of subjects: 20
Study 25713585 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone gel (Crinone 8% gel) + abstinence
Number of subjects: 20
Study 25713599 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 142
Study 25713599 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg
Number of subjects: 142
Study 25713599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 25713600 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 100
Study 25713600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initially in RCT phase)
Number of subjects: 100
Study 25713600 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg (initially in RCT phase)
Number of subjects: 100
Study 25713600 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 100
Study 25713900 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent double-balloon endoscopy (DBE)
Number of subjects: 30
Study 25713900 — intervention group
Group type: COMPARATOR
Intervention: Urgent video capsule endoscopy (VCE)
Number of subjects: 30
Study 25713900 — intervention group
Group type: COMPARATOR
Intervention: Both tests (DBE and VCE)
Number of subjects: 30
Study 25714519 — intervention group
Group type: EXPERIMENTAL
Intervention: Early WMAs predictors
Number of subjects: 301
Study 25714519 — intervention group
Group type: EXPERIMENTAL
Intervention: Late WMAs predictors
Number of subjects: 301
Study 25714828 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (vitamin K antagonists, factor Xa inhibitors, direct thrombin inhibitors)
Number of subjects: 17184
Study 25714828 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 17184
Study 25715311 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper Bromide Laser
Number of subjects: 0
Study 25715311 — intervention group
Group type: COMPARATOR
Intervention: Triple-Combination Cream
Number of subjects: 0
Study 25715403 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic treatment
Number of subjects: 575
Study 25715872 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization during mechanical ventilation
Number of subjects: 192
Study 25715872 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises in bed (N=94, 7%), standing at the bedside (N=11, 0.9%), walking (N=26, 2%)
Number of subjects: 192
Study 25716221 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (bisoprolol for at least 48 hours)
Number of subjects: 48
Study 25716221 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (chronic group)
Number of subjects: 48
Study 25716544 — intervention group
Group type: EXPERIMENTAL
Intervention: DEBIO1143 (oral administration, doses from 5 to 900 mg)
Number of subjects: 31
Study 25716544 — intervention group
Group type: EXPERIMENTAL
Intervention: DEBIO1143 (oral administration, doses >80 mg)
Number of subjects: 31
Study 25716544 — intervention group
Group type: EXPERIMENTAL
Intervention: DEBIO1143 (oral administration)
Number of subjects: 31
Study 25717286 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg twice daily or 15 mg twice daily for 3 weeks followed by 15 mg once daily)
Number of subjects: 100
Study 25717286 — intervention group
Group type: COMPARATOR
Intervention: UFH/warfarin (activated partial thromboplastin time-adjusted intravenous unfractionated heparin followed by warfarin)
Number of subjects: 100
Study 25717286 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 100
Study 25717286 — intervention group
Group type: COMPARATOR
Intervention: UFH/warfarin
Number of subjects: 100
Study 25719453 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 20/3 mg/kg twice-daily for 2 weeks, then adjusted to 25/3 mg/kg for patients <15 kg and 375/50 mg for patients 15 to <20 kg with an optimized background regimen (OBR)
Number of subjects: 21
Study 25719453 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir with OBR
Number of subjects: 21
Study 25719453 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Number of subjects: 21
Study 25719540 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound (HIFU)
Number of subjects: 15
Study 25720077 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Luteinising Hormone (LH)
Number of subjects: 40
Study 25720077 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Pregnanediol-3-glucuronide (P3G)
Number of subjects: 40
Study 25720077 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Estrone-3-glucuronide (E3G)
Number of subjects: 40
Study 25720077 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone (FSH)
Number of subjects: 40
Study 25720673 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 status assessed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)
Number of subjects: 213
Study 25720673 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 status and overall survival (OS) analysis
Number of subjects: 213
Study 25720673 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 mRNA expression
Number of subjects: 213
Study 25720673 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro analysis of HER2 mutation V777L
Number of subjects: 213
Study 25721307 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1152
Number of subjects: 0
Study 25721728 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 103
Study 25721728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular Ultrasound (IVUS)
Number of subjects: 103
Study 25721728 — intervention group
Group type: COMPARATOR
Intervention: Control group (485 STEMI patients without additional imaging)
Number of subjects: 103
Study 25721728 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural complications
Number of subjects: 103
Study 25721902 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (F)
Number of subjects: 227
Study 25721902 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine plus cyclophosphamide (FC)
Number of subjects: 227
Study 25722272 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of serum anti-tissue transglutaminase antibodies during febrile illness
Number of subjects: 0
Study 25722745 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-sequencing on the Illumina platform
Number of subjects: 3979
Study 25723529 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude exposure at 1630 m
Number of subjects: 51
Study 25723529 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude exposure at 2590 m
Number of subjects: 51
Study 25723529 — intervention group
Group type: COMPARATOR
Intervention: Altitude exposure at 490 m
Number of subjects: 51
Study 25724984 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe storage intervention
Number of subjects: 0
Study 25724984 — intervention group
Group type: COMPARATOR
Intervention: Legislative intervention
Number of subjects: 0
Study 25724984 — intervention group
Group type: COMPARATOR
Intervention: Medical management intervention
Number of subjects: 0
Study 25724984 — intervention group
Group type: COMPARATOR
Intervention: Follow-up contact intervention
Number of subjects: 0
Study 25724984 — intervention group
Group type: COMPARATOR
Intervention: Mobile phone contact intervention
Number of subjects: 0
Study 25726315 — intervention group
Group type: EXPERIMENTAL
Intervention: LES electrical stimulation therapy (LES-EST) at 20 Hz, 215 μs, 3-8 mAmp, delivered over 30-minute sessions, 6-12 sessions per day, starting on day 1 after implantation.
Number of subjects: 25
Study 25726315 — intervention group
Group type: EXPERIMENTAL
Intervention: LES electrical stimulation therapy (LES-EST)
Number of subjects: 25
Study 25727057 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment from the side of the bed
Number of subjects: 125
Study 25727057 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment from the foot of the bed
Number of subjects: 125
Study 25727057 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment from the head of the bed
Number of subjects: 125
Study 25727057 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall visual assessment
Number of subjects: 125
Study 25727057 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of chest recoil from side and foot positions
Number of subjects: 125
Study 25727057 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of CPR rate
Number of subjects: 125
Study 25727117 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse programs
Number of subjects: 957
Study 25727117 — intervention group
Group type: COMPARATOR
Intervention: Other sectors (primary care, mental health, social and community programs)
Number of subjects: 957
Study 25727117 — intervention group
Group type: COMPARATOR
Intervention: Clients without a substance abuse history
Number of subjects: 957
Study 25728316 — intervention group
Group type: EXPERIMENTAL
Intervention: Encepur(®) Children (conventional/accelerated conventional schedule)
Number of subjects: 4
Study 25728316 — intervention group
Group type: COMPARATOR
Intervention: FSME-IMMUN(®) Junior (mixed series)
Number of subjects: 4
Study 25728526 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib (50 mg twice daily for 7 days in 21-day cycles)
Number of subjects: 249
Study 25728732 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild CKD (60-89 mL/min per 1.73 m²)
Number of subjects: 876
Study 25728756 — intervention group
Group type: EXPERIMENTAL
Intervention: Reveal LINQ insertable cardiac monitor (ICM)
Number of subjects: 30
Study 25730213 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal bowel-control device
Number of subjects: 110
Study 25730237 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain with endometriosis
Number of subjects: 49
Study 25730237 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain without endometriosis
Number of subjects: 49
Study 25730237 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 49
Study 25730237 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain with myofascial trigger points
Number of subjects: 49
Study 25730237 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain with high anxiety
Number of subjects: 49
Study 25730237 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain with high depression
Number of subjects: 49
Study 25730284 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal video capsule endoscopy (ECE)
Number of subjects: 330
Study 25730284 — intervention group
Group type: COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Number of subjects: 330
Study 25730284 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction (ECE)
Number of subjects: 330
Study 25730284 — intervention group
Group type: COMPARATOR
Intervention: Patient satisfaction (EGD)
Number of subjects: 330
Study 25730509 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy with raltegravir and Truvada during primary HIV infection (PHI)
Number of subjects: 16
Study 25730509 — intervention group
Group type: COMPARATOR
Intervention: Early antiretroviral therapy with raltegravir and Truvada during chronic HIV infection (CHI)
Number of subjects: 16
Study 25730509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts (PHI and CHI)
Number of subjects: 16
Study 25731869 — intervention group
Group type: EXPERIMENTAL
Intervention: SSA/P-D
Number of subjects: 207
Study 25731869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer
Number of subjects: 207
Study 25731869 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and lesion size
Number of subjects: 207
Study 25731869 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenomatous pit pattern
Number of subjects: 207
Study 25731869 — intervention group
Group type: EXPERIMENTAL
Intervention: Paris 0-Is component
Number of subjects: 207
Study 25731869 — intervention group
Group type: EXPERIMENTAL
Intervention: HGD or cancer
Number of subjects: 207
Study 25731869 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and Paris 0-Is component
Number of subjects: 207
Study 25732635 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy based on ERCC1, RRM1, and TS protein expression
Number of subjects: 128
Study 25732635 — intervention group
Group type: COMPARATOR
Intervention: Non-individualized treatment
Number of subjects: 128
Study 25733005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat (MLN4924) administered via a 60-min intravenous infusion on days 1, 3 and 5 (schedule A) at maximum tolerated dose (MTD) of 59 mg/m².
Number of subjects: 53
Study 25733005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat (MLN4924) administered via a 60-min intravenous infusion on days 1, 4, 8 and 11 (schedule B) at maximum tolerated dose (MTD) of 83 mg/m².
Number of subjects: 53
Study 25733329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour measured by accelerometer over 7 days, assessing total sedentary time and sedentary time in bouts ≥10 min.
Number of subjects: 263
Study 25733329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour in bouts ≥10 min
Number of subjects: 263
Study 25733329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour in bouts ≥10 min after adjusting for potential confounders
Number of subjects: 263
Study 25733369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin for 24 weeks (n = 55)
Number of subjects: 114
Study 25733369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ledipasvir with or without GS-9669 or GS-9451 (n = 59)
Number of subjects: 114
Study 25733369 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HCV RNA ≥LLOQ at EOT
Number of subjects: 114
Study 25733630 — intervention group
Group type: EXPERIMENTAL
Intervention: Afebrile malaria treatment
Number of subjects: 41
Study 25733630 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookworm treatment
Number of subjects: 41
Study 25733630 — intervention group
Group type: EXPERIMENTAL
Intervention: S. haematobium treatment
Number of subjects: 41
Study 25733641 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to ACS cancer prevention guidelines (highest level)
Number of subjects: 476396
Study 25734008 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-transduced VSTs
Number of subjects: 0
Study 25734008 — intervention group
Group type: COMPARATOR
Intervention: Late-transduced VSTs
Number of subjects: 0
Study 25734107 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 812
Study 25734107 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) in TB patients
Number of subjects: 812
Study 25734107 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) in non-TB patients
Number of subjects: 812
Study 25734107 — intervention group
Group type: COMPARATOR
Intervention: Retention in care
Number of subjects: 812
Study 25734107 — intervention group
Group type: COMPARATOR
Intervention: Mortality
Number of subjects: 812
Study 25734107 — intervention group
Group type: COMPARATOR
Intervention: Loss to follow-up
Number of subjects: 812
Study 25734159 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine with AS03 adjuvant (3.75 µg HA)
Number of subjects: 0
Study 25734159 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine without AS03 adjuvant
Number of subjects: 0
Study 25734159 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine with AS03 adjuvant (7.5 µg HA)
Number of subjects: 0
Study 25734159 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine with AS03 adjuvant (15 µg HA)
Number of subjects: 0
Study 25734163 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO-TB screening followed by clinical scoring
Number of subjects: 812
Study 25734163 — intervention group
Group type: COMPARATOR
Intervention: WHO-TB screening alone
Number of subjects: 812
Study 25734163 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical scoring algorithm (0-1 points)
Number of subjects: 812
Study 25734163 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical scoring algorithm (≥4 points)
Number of subjects: 812
Study 25734163 — intervention group
Group type: COMPARATOR
Intervention: WHO-TB screening
Number of subjects: 812
Study 25734253 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 27
Study 25734254 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (0.06-0.24 mg/kg · d)
Number of subjects: 86